Adial Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Adial Pharmaceuticals is a biopharmaceutical business in the clinical stages that specialises on the creation of addiction treatments. The Company's lead investigational new drug product, AD04, is being studied in the Company's historic ONWARDTM Phase 3 clinical trial for the potential treatment of AUD in subjects with specific target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). There were no overt safety concerns in a Phase 2b clinical trial using AD04 for the treatment of AUD, however there were encouraging outcomes in terms of lowering frequency of drinking, quantity of drinking, and heavy drinking (all with statistical significance) (there were no statistically significant serious adverse events reported)
Adial Pharmaceuticals has raised $47.8M across 4 funding rounds on record, the most recent an undisclosed round of $32.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adial Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Adial Pharmaceuticals Funding Rounds
Adial Pharmaceuticals raised $5.0M in a Post-IPO Equity announced in Jul 2021.
7 months later, a Post-IPO Equity of $10.0M was announced in Feb 2022.
1 years later, an undisclosed round of $750k was announced in Feb 2023.
3.3 years later, an undisclosed round of $32.0M was announced in Jun 2026.
Adial Pharmaceuticals Founders and Leadership Team
Contact details for the Adial Pharmaceuticals team: 2 of 2 have an email address on file.
Start 14-day free trial →Adial Pharmaceuticals Funding Compared to Other Biotechnology Startups
Adial Pharmaceuticals' latest round of $32.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adial Pharmaceuticals in Biotechnology and Charlottesville
Companies Similar to Adial Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Adial Pharmaceuticals Funding FAQs
What does Adial Pharmaceuticals do?
Adial Pharmaceuticals is a biopharmaceutical business in the clinical stages that specialises on the creation of addiction treatments. The Company's lead investigational new drug product, AD04, is being studied in the Company's historic ONWARDTM Phase 3 clinical trial for the potential treatment of AUD in subjects with specific target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). There were no overt safety concerns in a Phase 2b clinical trial using AD04 for the treatment of AUD, however there were encouraging outcomes in terms of lowering frequency of drinking, quantity of drinking, and heavy drinking (all with statistical significance) (there were no statistically significant serious adverse events reported)
How much funding has Adial Pharmaceuticals raised?
Adial Pharmaceuticals has raised $47.8M across 4 rounds on record. The most recent is an undisclosed round of $32.0M announced in Jun 2026.
When did Adial Pharmaceuticals last raise funding?
Adial Pharmaceuticals' most recent funding round on record is an undisclosed round of $32.0M, announced in Jun 2026.
Who founded Adial Pharmaceuticals?
FundedIQ lists Cary Claiborne (Founder) at Adial Pharmaceuticals.
Who is the CEO of Adial Pharmaceuticals?
William Stilley is listed as CEO at Adial Pharmaceuticals.
Where is Adial Pharmaceuticals headquartered?
Adial Pharmaceuticals is based in Charlottesville, Virginia, United States.
How many employees does Adial Pharmaceuticals have?
Adial Pharmaceuticals is in the 11-50 employee band.
How does Adial Pharmaceuticals' funding compare to other Biotechnology startups?
Adial Pharmaceuticals' latest round of $32.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Adial Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adial Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.